Cargando…
Lung cancer metastasis-related protein 1 promotes the transferring from advanced metastatic prostate cancer to castration-resistant prostate cancer by activating the glucocorticoid receptor α signal pathway
Androgen deprivation therapy is currently the main therapeutic strategy for the treatment of advanced metastatic prostate cancer (ADPC). However, the tumor type in ADPC patients transforms into castration-resistant prostate cancer (CRPC) after 18–24 months of treatments, the underlying mechanism of...
Autores principales: | Wang, Kai, Wang, Xuliang, Fu, Xian, Sun, Ji, Zhao, Liwei, He, Huadong, Fan, Yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974197/ https://www.ncbi.nlm.nih.gov/pubmed/35184651 http://dx.doi.org/10.1080/21655979.2021.2020397 |
Ejemplares similares
-
Reappraisal of glucocorticoids in castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014) -
Glucocorticoid receptor-induced non-muscle caldesmon regulates metastasis in castration-resistant prostate cancer
por: Virtanen, Verneri, et al.
Publicado: (2023) -
Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis
por: He, Lugeng, et al.
Publicado: (2020) -
Predictors for progression of metastatic prostate cancer to castration-resistant prostate cancer in Indians
por: Sureka, Sanjoy Kumar, et al.
Publicado: (2016) -
Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients
por: Lin, Ting-Ting, et al.
Publicado: (2019)